UNASSIGNED: In spite of initial intravenous immunoglobulin (IVIG) treatment, a significant number of @entity1 are unresponsive to it and are at a higher risk for @entity453 . @entity288 have been used as a secondary drug or used in combination with IVIG. Three options of using @entity288 for the treatment of @entity1 during the acute phase of @entity573 , have been considered. The first is their use exclusively for @entity1 unresponsive to IVIG treatment. The second is their use in combination with IVIG as the routine first line therapy for all @entity1 . The last is the use in the combination as the first line therapy for selected @entity1 at a high risk being unresponsive to initial IVIG. However, it is uncertain that the @entity288 as the second line treatment are better than the additional IVIG in @entity1 unresponsive to initial IVIG. The combination of @entity288 and IVIG as the routine first line therapy also have not enough evidences. The last option of using @entity288 - the combination of @entity288 and IVIG in @entity1 at high risk of unresponsiveness, is a properly reasonable treatment strategy. However, there have been no globally standardized predictive models for the unresponsiveness to initial IVIG treatment. Therefore, future investigations to determine the best predictive model are necessary.

Use of @entity288 during acute phase of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery lesions'] @entity573 :: ('MESH:C537014', 'Disease') :: ['Kawasaki disease'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids', 'Corticosteroids']
@entity573 :: (MESH:C537014,Disease) :: ['Kawasaki disease']
